Chemistry:Alixorexton

From HandWiki

Alixorexton (INN; developmental code name ALKS-2680) is an orexin receptor agonist which is under development for the treatment of sleep disorders, including narcolepsy and idiopathic hypersomnia.[1][2][3] Alixorexton is being developed by Alkermes[4] As of July 2025, it is in phase 2 clinical trials with planned advancement to a phase 3 study for the treatment of narcolepsy type 1.[4]

See also

References

  1. ↑ "Alixorexton - Alkermes". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800066491. 
  2. ↑ "Enhancing the Management of Hypersomnia: Examining the Role of the Orexin System". Seminars in Neurology 45 (3): 410–419. May 2025. doi:10.1055/a-2589-3825. PMID 40239951. 
  3. ↑ "Dreaming of Better Treatments: Advances in Drug Development for Sleep Medicine and Chronotherapy". Journal of Sleep Research 34 (5). May 2025. doi:10.1111/jsr.70087. PMID 40346938. 
  4. ↑ 4.0 4.1 "Alkermes drug helped narcolepsy patients stay awake in Phase 2 trial" (in en-US). 2025-07-21. https://www.statnews.com/2025/07/21/alkermes-drug-narcolepsy-alixorexton-results/. 

Template:Wakefulness-promoting agents



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Alixorexton&oldid=4243740"